Intended for healthcare professionals

Rapid response to:

News

UK government pushes ahead with value based pricing of drugs

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4632 (Published 20 July 2011) Cite this as: BMJ 2011;343:d4632

Rapid Response:

Health policy or economic policy?

Medicines, Pharmacy and Industry are under one roof in the Department
of Health - this in itself leads to conflict of interest and priorities.
Health Policy is asking for dual delivery of efficiencies and quality
(productivity) in terms of optimising outcomes from medicines, one of the
most frequently made interventions in the NHS. Yet in the same department
in DH decisions are made about pricing of drugs, and impact the
pharmaceutical industry has on UK economy and its link to reference
pricing.

Prior to any introduction of VBP, two issues need to be addressed -
that of health policy versus economic policy champions being under one
roof, and the governance surrounding orphan drugs.

Competing interests: No competing interests

15 August 2011
Neeshma Shah
Head of Medicines Management
NHS NCL Camden borough